Active Clinical Trials
Clinical trials are at the heart of our work to bring innovative medicines to people with a particular disease or condition. Learn more about the active studies conducted by Novartis including opportunities to get involved.
- Sort by Sort ascending
- Study title
- Condition
- Phase
- Location
- NCT ID
| Study title | Condition | Phase | Location | NCT ID |
|---|---|---|---|---|
Study of HRO761 Alone or in Combination in Cancer Patients With Specific DNA Alterations Called Microsatellite Instability or Mismatch Repair Deficiency. |
MSIhi or dMMR Advanced Unresectable or Metastatic Solid Tumors, Including Colorectal Cancers | Phase1 | Belgium China France Germany Israel Italy Japan Norway Singapore South Korea Spain Sweden Taiwan United Kingdom United States View all |
NCT05838768 |
Phase 3 Extension Study to Evaluate Long-term Safety of Ianalumab in Participants With Systemic Lupus Erythematosus (SIRIUS-SLE Extension). |
Systemic Lupus Erythematosus | Phase3 | Argentina Australia Brazil Bulgaria Canada Chile China Colombia Czechia France Germany Guatemala Hungary India Israel Italy Japan Malaysia Mexico Poland Portugal Romania South Africa South Korea Spain Taiwan Thailand United States View all |
NCT06133972 |
Asciminib Prospective Non Interventional Study as 3rd Line Therapy or More to Treat Adult Patients With CML- CP in Real World Setting in France |
Chronic Myeloid Leukemia | France | NCT06092879 | |
[177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanced Breast Cancer |
Breast Cancer | Phase1 | China France Germany Poland Portugal Spain United States View all |
NCT05870579 |
Evaluate Long-term Safety, Tolerability and Efficacy of Iptacopan in Study Participants With aHUS |
Atypical Hemolytic Uremic Syndrome | Phase3 | Brazil China Czechia India View all |
NCT05795140 |
Kesimpta (Ofatumumab) Pregnancy Registry |
Multiple Sclerosis, Pregnancy | United States | NCT05634967 | |
Ribociclib (LEE011) Rollover Study for Continued Access |
Continued Access to Study Treatment(s), Cancers With a Mass, Bulky Tumor, Nodule, Lump, Advanced Cancer, Advanced Solid Tumors, Advanced Solid Malignancies | Phase2 | Taiwan United States |
NCT02934568 |
Clinical Study To Further Evaluate The Efficacy Of Dabrafenib Plus Trametinib In Patients With Rare BRAF V600E Mutation-Positive Unresectable or Metastatic Solid Tumors |
Rare Unresectable or Metastatic BRAF V600E Mutation-positive Solid Tumors | United States | NCT05868629 | |
A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers |
Carcinoma, Non-Small-Cell Lung, Cutaneous Melanoma, Carcinoma, Renal Cell, Carcinoma, Ovarian Epithelial, Nasopharyngeal Carcinoma, Carcinoma, Thymic, Anal Cancer, Mesothelioma, Esophagogastric Cancer, High Microsatellite Instability Colorectal Carcinoma, Squamous Cell Carcinoma of Head and Neck, Triple Negative Breast Neoplasms | Phase1 | Canada China France Germany Hong Kong Italy Japan Singapore South Korea Spain Taiwan United States View all |
NCT05544929 |
Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers |
Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, HR+/HER2- Ductal and Lobular Breast Cancer, Triple Negative Breast Cancer, Colorectal Cancer | Phase1 | Belgium Canada France Israel Italy Netherlands Spain Switzerland United States View all |
NCT06562192 |